-
Je něco špatně v tomto záznamu ?
PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study
A. Martinez, F. Lecuru, N. Bizzarri, C. Chargari, A. Ducassou, A. Fagotti, F. Fanfani, G. Scambia, D. Cibula, B. Díaz-Feijoo, A. Gil Moreno, MA. Angeles, MZ. Muallem, C. Kohler, M. Luyckx, F. Kridelka, A. Rychlik, KG. Gerestein, V. Heinzelmann,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu randomizované kontrolované studie, multicentrická studie, časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 2018-01-01 do 2024-12-31
Health & Medicine (ProQuest)
od 2018-01-01 do 2024-12-31
PubMed
36717163
DOI
10.1136/ijgc-2022-004223
Knihovny.cz E-zdroje
- MeSH
- lidé MeSH
- lokální recidiva nádoru patologie MeSH
- lymfadenektomie metody MeSH
- lymfatické metastázy patologie MeSH
- lymfatické uzliny chirurgie patologie MeSH
- nádory děložního čípku * chirurgie patologie MeSH
- PET/CT * MeSH
- retrospektivní studie MeSH
- staging nádorů MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Positron emission tomography/computed tomography (PET/CT) fails to detect approximately 25% of aortic lymph node metastasis in patients with PET/CT stage IIIC1 cervical cancer. Surgical staging could lead to treatment modification and to improved para-aortic and distant control. PRIMARY OBJECTIVES: To demonstrate if chemoradiation with tailored external beam radiation field based on surgical staging and pathologic examination of the para-aortic lymph node is associated with improved 3-year disease-free survival compared with patients staged with PET/CT staging only. STUDY HYPOTHESIS: Surgical staging followed by tailored chemoradiation will improve disease-free survival while avoiding unnecessary prophylactic extended-field chemoradiation in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC1 cervical cancer. TRIAL DESIGN: This is an international multicenter, randomized, phase III study. Eligible patients will be randomized 1:1 between PET/CT staging followed by chemoradiation (control arm), or surgical staging followed by tailored chemo-radiation (experimental arm). Randomization will be stratified by tumor stage according to TNM classification, center, and adjuvant treatment. MAJOR INCLUSION/EXCLUSION CRITERIA: Main inclusion criteria are histologically proven PET/CT FIGO stage IIIC1 cervical cancer. Main exclusion criteria include unequivocal positive common iliac or para-aortic lymph node at pre-therapeutic imaging PET/CT. PRIMARY ENDPOINTS: The primary endpoint is disease-free survival defined as the time from randomization until first relapse (local, regional, or distant), or death from any cause. SAMPLE SIZE: 510 eligible patients ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The estimated date for completing accrual will be Q2 2027. The estimated date for presenting results will be Q4 2030. TRIAL REGISTRATION NUMBER: NCT05581121.
Breast Gynecology and Reconstructive Surgery Unit Institute Curie Paris France
Centre de Recherches en Cancérologie de Toulouse INSERM UMR 1037 Toulouse France
Department of Obstetrics and Gynaecology University Medical Centre Utrecht Utrecht The Netherlands
Department of Obstetrics and Gynecology University of Liège Liege Belgium
Gynaecologic Oncology Imperial College London Faculty of Medicine London London UK
Maria Sklodowska Curie National Research Institute of Oncology in Warsaw Warsaw Poland
Obstetric and Gynaecology University of Basel Faculty of Medicine Zurich Switzerland
Radiotherapy Department Hôpital Pitié Salpêtrière AP HP Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004241
- 003
- CZ-PrNML
- 005
- 20230425141229.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1136/ijgc-2022-004223 $2 doi
- 035 __
- $a (PubMed)36717163
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Martinez, Alejandra $u Surgical Oncology Department, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France martinez.alejandra@iuct-oncopole.fr $u Centre de Recherches en Cancérologie de Toulouse, INSERM UMR 1037, Toulouse, France $1 https://orcid.org/0000000276333536
- 245 10
- $a PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study / $c A. Martinez, F. Lecuru, N. Bizzarri, C. Chargari, A. Ducassou, A. Fagotti, F. Fanfani, G. Scambia, D. Cibula, B. Díaz-Feijoo, A. Gil Moreno, MA. Angeles, MZ. Muallem, C. Kohler, M. Luyckx, F. Kridelka, A. Rychlik, KG. Gerestein, V. Heinzelmann, PT. Ramirez, M. Frumovitz, G. Ferron, S. Betrian, T. Filleron, C. Fotopoulou, D. Querleu, PAROLA Study group
- 520 9_
- $a BACKGROUND: Positron emission tomography/computed tomography (PET/CT) fails to detect approximately 25% of aortic lymph node metastasis in patients with PET/CT stage IIIC1 cervical cancer. Surgical staging could lead to treatment modification and to improved para-aortic and distant control. PRIMARY OBJECTIVES: To demonstrate if chemoradiation with tailored external beam radiation field based on surgical staging and pathologic examination of the para-aortic lymph node is associated with improved 3-year disease-free survival compared with patients staged with PET/CT staging only. STUDY HYPOTHESIS: Surgical staging followed by tailored chemoradiation will improve disease-free survival while avoiding unnecessary prophylactic extended-field chemoradiation in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC1 cervical cancer. TRIAL DESIGN: This is an international multicenter, randomized, phase III study. Eligible patients will be randomized 1:1 between PET/CT staging followed by chemoradiation (control arm), or surgical staging followed by tailored chemo-radiation (experimental arm). Randomization will be stratified by tumor stage according to TNM classification, center, and adjuvant treatment. MAJOR INCLUSION/EXCLUSION CRITERIA: Main inclusion criteria are histologically proven PET/CT FIGO stage IIIC1 cervical cancer. Main exclusion criteria include unequivocal positive common iliac or para-aortic lymph node at pre-therapeutic imaging PET/CT. PRIMARY ENDPOINTS: The primary endpoint is disease-free survival defined as the time from randomization until first relapse (local, regional, or distant), or death from any cause. SAMPLE SIZE: 510 eligible patients ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: The estimated date for completing accrual will be Q2 2027. The estimated date for presenting results will be Q4 2030. TRIAL REGISTRATION NUMBER: NCT05581121.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a PET/CT $7 D000072078
- 650 12
- $a nádory děložního čípku $x chirurgie $x patologie $7 D002583
- 650 _2
- $a lymfatické metastázy $x patologie $7 D008207
- 650 _2
- $a lokální recidiva nádoru $x patologie $7 D009364
- 650 _2
- $a lymfadenektomie $x metody $7 D008197
- 650 _2
- $a lymfatické uzliny $x chirurgie $x patologie $7 D008198
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lecuru, Fabrice $u Breast, Gynecology and Reconstructive Surgery Unit, Institute Curie, Paris, France
- 700 1_
- $a Bizzarri, Nicolò $u Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy $1 https://orcid.org/000000021727904X
- 700 1_
- $a Chargari, Cyrus $u Radiotherapy Department, Hôpital Pitié-Salpêtrière AP-HP, Paris, France
- 700 1_
- $a Ducassou, Anne $u Radiotherapy Department, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse Oncopole, France, Toulouse, France
- 700 1_
- $a Fagotti, Anna $u Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy $1 https://orcid.org/000000015579335X
- 700 1_
- $a Fanfani, Francesco $u Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy $1 https://orcid.org/0000000319917284
- 700 1_
- $a Scambia, Giovanni $u Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy $1 https://orcid.org/0000000327581063
- 700 1_
- $a Cibula, David $u Gynecologic Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital (Central and Eastern European Gynecologic Oncology Group CEEGOG), Prague, Czech Republic
- 700 1_
- $a Díaz-Feijoo, Berta $u Institute Clinic of Gynecology, Obstetrics and Neonatology, Hospital Clinic de Barcelona, Institutd'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain $1 https://orcid.org/0000000264511817
- 700 1_
- $a Gil Moreno, Antonio $u Gynecologic Oncology, Department of Obstetrics and Gynecology, Vall d'Hebron University Hospital, Barcelona, Spain
- 700 1_
- $a Angeles, Martina Aida $u Gynecologic Oncology, Department of Obstetrics and Gynecology, Vall d'Hebron University Hospital, Barcelona, Spain $1 https://orcid.org/0000000344013084
- 700 1_
- $a Muallem, Mustafa Zelal $u Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany
- 700 1_
- $a Kohler, Christhardt $u Department of Special Operative and Oncologic Gynecology, Asklepios-Clinic Hamburg-Altona, Asklepios Hospital Group, Hamburg, Germany
- 700 1_
- $a Luyckx, Mathieu $u Department of Gynecology-Andrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
- 700 1_
- $a Kridelka, Frederic $u Department of Obstetrics and Gynecology, University of Liège, Liege, Belgium
- 700 1_
- $a Rychlik, Agnieszka $u Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warsaw, Poland $1 https://orcid.org/0000000288608883
- 700 1_
- $a Gerestein, K G $u Department of Obstetrics and Gynaecology, University Medical Centre Utrecht, Utrecht, The Netherlands
- 700 1_
- $a Heinzelmann, Viola $u Obstetric and Gynaecology, University of Basel Faculty of Medicine, Zurich, Switzerland
- 700 1_
- $a Ramirez, Pedro T $u Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, Texas, USA $1 https://orcid.org/0000000263708052
- 700 1_
- $a Frumovitz, Michael $u Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, Texas, USA $1 https://orcid.org/0000000208102648
- 700 1_
- $a Ferron, Gwenael $u Surgical Oncology Department, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France $1 https://orcid.org/0000000285454700
- 700 1_
- $a Betrian, Sarah $u Medical Oncology Department, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
- 700 1_
- $a Filleron, Thomas $u Biostatistics & Health Data Science Unit, Institut Claudius Regaud, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
- 700 1_
- $a Fotopoulou, Christina $u Gynaecologic Oncology, Imperial College London Faculty of Medicine, London, London, UK $1 https://orcid.org/0000000163759645
- 700 1_
- $a Querleu, Denis $u Fondazione Policlinico Universitario A. Gemelli, IRCCS, UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy $1 https://orcid.org/0000000239844812
- 710 2_
- $a PAROLA Study group
- 773 0_
- $w MED00009896 $t International journal of gynecological cancer : official journal of the International Gynecological Cancer Society $x 1525-1438 $g Roč. 33, č. 2 (2023), s. 293-298
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36717163 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141225 $b ABA008
- 999 __
- $a ok $b bmc $g 1924732 $s 1190450
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 33 $c 2 $d 293-298 $e 20230206 $i 1525-1438 $m International journal of gynecological cancer $n Int J Gynecol Cancer $x MED00009896
- LZP __
- $a Pubmed-20230418
